The differential expression of soluble programmed death ligand 1 (sPD-L1) has been found in some cancers; however, the correlation between sPD-L1 expression and prognosis value in tumour is still unclear. Here, we conducted a metaanalysis and systematic review to assess the prognostic value of sPD-L1 in patients with cancer. Eligible studies were searched for in the databases including PubMed, Web of Science, ScienceDirect and Wiley Online Library database. The pooled hazard ratios (HRs) with a 95% confidence interval (95%CI) were calculated to assess the prognostic significance of sPD-L1 in human cancer. Eight studies and 1102 patients with cancer were included in the final analysis, and the combined analysis indicated that a higher level of sPD-L1 was associated with worse overall survival (OS) (HR = 1.60, 95%CI: 1.21-1.99). Furthermore, statistical significance was also observed in subgroup analysis stratified by the cancer type (haematological neoplasms or non-haematological neoplasms), sample size (more or less than 100), cut-off value of sPD-L1 (more or less than 6.51 ng/ml) and ethnicity (Asian or European). The meta-analysis indicates that circulating sPD-L1 changes may serve as a useful biomarker for cancer prognosis, and higher level of sPD-L1 may also be associated with poor outcomes in patients with cancer.
Introduction
The incidence and mortality of malignant tumours in the world are increasing, and cancer has become a serious threat to human life [1] . Despite new methods of treatment come out every year, the prognosis in some cancers has a considerable improvement. However, the current status of cancer is that the 5-year survival rate is still low. Thus, there is an urgent need to identify reliable biomarkers to help early diagnosis, prevention and treatment of cancers [2, 3] .
Programmed death-1 (PD-1) is an immunoglobulin superfamily type I transmembrane glycoprotein consisting of 288 amino acids, which is expressed on different immune cells, especially on T cells. Programmed death ligand 1 (PD-L1) is one ligand of PD-1. Soluble programmed death ligand 1 (sPD-L1) is released from PD-L1-positive cells, which binds to receptor of PD-1, participates in immunoregulation [4] . Furthermore, sPD-L1 was found to be involved in tumour-associated immune suppression and host immune damage, thereby promoting cancer progression and subsequent adverse clinical outcomes [5, 6] . In addition, high level of sPD-L1 maybe also associated with the prognosis of malignancies, including lung cancer [7] , multiple myeloma [8] , extranodal NK/T cell lymphoma [9] and so on [6, 10] .
However, the correlation between sPD-L1 level and prognosis in tumour is needed to be further explored. Here, we carried out a systematic meta-analysis to assess the prognostic value of sPD-L1 in cancers, and thereby further discuss whether sPD-L1 could be served as a reliable biomarker in tumours.
Materials and methods
Literature search. Potential eligible studies were collected and reviewed in electronic databases (PubMed, Web of Science, ScienceDirect and Wiley Online Library), and the last update of searching time was March 14, 2017 . The search criteria were limited to articles published in the English language. The keywords for the search were as follows: 'soluble programmed death ligand 1', 'sPD-L1', 'cancer', 'tumour', 'carcinoma' and 'neoplasm'.
Inclusion and exclusion criteria. The articles of inclusion and exclusion were carried out independently by two investigators. Inclusion criteria as follows: (1) all studies were to investigate the relationship between the sPD-L1 and prognosis in tumour; (2) the levels of sPD-L1 expression were detected by enzyme-linked immunosorbent assay (ELISA); (3) sPD-L1 was measured by ELISA without any formal treatment; (4) patients were divided into two groups according to the level of sPD-L1; (5) all studies containing sufficient data to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CI).
Exclusion criteria as follows: (1) studies without available data; (2) duplicated publications; (3) studies only investigated the molecular structure and functions of sPD-L1; (4) letters, reviews, case reports and expert opinions.
Data extraction and quality assessment. All eligible studies and information data were extracted by two independent investigators (YY, Ding and C, Sun). The following information and data were recorded: first author, year, country, ethnicity, tumour type, sample size, sPD-L1 level (high level and low level), HR, outcome and NewcastleOttawa Quality Assessment Scale (NOS) ( Table 1 ). If only Kaplan-Meier curve was provided, the survival data were extracted with the GetData Graph Digitizer software (http://getdata-graphdigitizer.com/) and the hazard ratios (HRs) with 95% confidence intervals (95% CI) are estimated according to the method introduced by Tierney et al. [11] . The Newcastle-Ottawa Quality Assessment Scale (NOS) was used as an assessment of the quality of the study, the NOS contained three parts: selection (four points), comparability (two points) and outcome assessment (three points), and details about NOS score of eligible studies are shown in Table 2 . Two investigators (YY, Ding and C, Sun) assessed the quality of each study independently, and the study with an NOS score ≥6 was considered to be of high quality.
Statistical methods. Data were extracted from the articles and analysed using STATA12 (Stata Corp, College Station, TX). Statistical heterogeneity was tested by Cochran Q test and I 2 statistic. For insignificant heterogeneity among studies (Cochran Q test: P heterogeneity > 0.10 or I 2 < 50%), the fixed-effects model was used to estimate the pooled HR, and if not, the random-effects model was used. All statistical tests were two-sided, and P < 0.05 was considered as statistically significant. Publication bias was tested with Begg's and Egger's tests.
Results

Characteristics of the included studies
Schedule of search and screening is presented in Fig. 1 . According to the inclusion criteria, eight studies involving a total of 1102 patients, and the patient sample size ranges from 58 to 288 with a median sample size value of 103. Six of the included studies were conducted in Asian, and the remaining two studies were conducted in European. Eight types of human cancer were included in this analysis with non-small cell lung cancer (NSCLC), lung cancer (LC), multiple myeloma (MM), biliary tract cancer (BTC), diffuse large B cell lymphoma (DLBCL), gastric adenocarcinoma (GA), extranodal NK/T cell lymphoma (ENKTCL) and hepatocellular carcinoma (HCC). The levels of sPD-L1 were detected by ELISA, and all included studies consisted of two groups: high and low levels of sPD-L1. Characteristics of different assays are shown in Table 3 .
The association between the levels of sPD-L1 and OS in cancer
As shown in Table 4 , eight studies involving a total of 1102 patients were included in the analysis. Pooled hazard ratios (HRs) and the respective 95% confidence interval (CI) were studied to estimate the association between sPD-L1 level and OS. The HR of the high sPD-L1 group versus the low sPD-L1 group was 1.60 (95% CI: 1.21-1.99, P < 0.01) ( Fig. 2A ) with no heterogeneity (I 2 = 4.1%, P heterogeneity = 0.389). The data also showed that there was a significant difference in OS between the two groups, and the result indicated that there existed a significantly positive association between elevated level of sPD-L1 and poor OS. Furthermore, we performed a subgroup analysis to assess the effect of cancer type, sample size, ethnicity and cut-off value on OS.
Firstly, according to the type of patients with cancer, we divided patients with cancer into two groups with or without haematological neoplasms patients. The results shown that cases with high level of sPD-L1 presented poor OS in both studies of haematological neoplasms (HR = 1.14, 95% CI: 0.34-1.95; fixed-effects model) and non-haematological neoplasms patients (HR = 1.75, 95% CI: 1.30-2.19; fixed-effects model) (Fig. 2B) .
Secondly, with 100 patients as a threshold, the sample size was divided into two categories, the results shown that high level of sPD-L1 in predicting poor OS in both sample 
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Letters, reviews, case reports and expert opinions size <100 (HR = 1.17, 95% CI: 0.38-1.96; fixed-effects model) and sample size ≥100 (HR = 1.74, 95% CI: 1.30-2.19; fixed-effects model) (Fig. 2C) . Thirdly, according to the ethnicity of the study, we divided all patients with cancer into European and Asian group, the results shown that high level of sPD-L1 in predicting poor OS in both European (HR = 2.29, 95% CI: 1.10-3.49; fixed-effects model) and Asian (HR = 1.52, 95% CI: 1.11-1.93; fixed-effects model) (Fig. 2D) . Finally, the studies were divided into two categories based on Mean + 2SD (6.51 ng/ml) of the optimal cut-off values included in the meta-analysis, which was also statistically significant, and similar results were found in the effects of high level of sPD-L1 on OS (Fig. 2E) .
Publication bias and sensitivity analysis
In order to assess publication bias, we used Begg's funnel plots and Egger's test to assess this meta-analysis, and the results of Begg's test (P = 0.536) and Egger's test (P = 0.854) revealed no publication bias for OS. Funnel plot showed no evidence of obvious asymmetry for OS (Fig. 3) . of sPD-L1 365   ................................................................................................................................................................ ..
Discussion
Chemotherapy, radiotherapy and surgery are the most commonly used methods of treating cancer. In recent years, with the emergence of new therapies, especially immunotherapy has become a hot spot, and PD-1-based immunotherapeutic drugs are most well known. PD-1, an important immunosuppressive molecule, was originally obtained using subtractive hybridization technique from mouse hybridomas and haematopoietic progenitor cell lines cloned from mice [15] . It is expressed on different immune cells included CD4+ and CD8+ T cells, NK, B cells and monocytes, especially on T cells [16] . PD-L1 and PD-L2 are ligands of PD-1 [17, 18] . When PD-L1 and PD-1 are combined, PD-1 transmits inhibitory signals, which play a variety of biological functions including regulate immune responses, establish immune tolerance and prevent autoimmune diseases. Furthermore, PD-1/PD-L1 pathway was found to play a critical role in tumour immunity [19] . Many studies have shown that tumour cells overexpressing PD-L1 [20, 21] , which binds to PD-1, can attenuate the body's antitumour immune response and help the tumour cells evade the immune system. In addition, studies have indicated that high level of PD-L1 expression is a negative prognostic factor in cancers [22, 23] and anti-PD-1/PD-L1 antibody therapy may significantly improve the outcomes [24, 25] .
SPD-L1, a protein, was originally detected by sandwich enzyme-linked immunosorbent assay (ELISA) from human serum and was found to be released from PD-L1 positive cells. An amount of sPD-L1 could bind to PD-1, affects the activated T cells and increases the complexity of PD-1/PD-L1 co-inhibitory signal in immune regulation [4] . Lots of efforts have been made to understand the functional role of sPD-L1 in cancer and indicate that sPD-L1 may represent the extent of intrinsic T cell response in tumour tissue and resultant immune suppression mediated by the immune checkpoint mechanism of the PD-1/PD-L1 axis [7, 26] . Accordingly, sPD-L1 may act as a reliable biomarker. Here, so we carried out the meta-analysis to explore prognostic significance of sPD-L1 in patients with cancer and further discussed whether sPD-L1 could be served as a reliable biomarker in tumours.
In this meta-analysis, screening was conducted through a series of selection criteria, which eventually included eight studies on eight categories of malignancies for a total of 1102 patients, and evaluated the value of sPD-L1 in the prognosis of cancer through context. The combined results indicated that higher level of sPD-L1 was associated with worse overall survival. Furthermore, we also performed subgroup analysis stratified by cancer type, sample size; ethnicity, cut-off values, and similar results were found in regard to the effects of high level of sPD-L1 on OS. In these eight studies, only two articles [8, 9] studied the relationship between the sPD-L1 expression and progression-free survival (PFS), due to the limited number of samples, we did not analyse the relationship between sPD-L1 and PFS, but the results of the two investigators' shown that high level of sPD-L1 was also associated with poor PFS in patients with cancer.
The reliability of the results of the meta-analysis is unavoidably related to heterogeneity; thus, the results were combined and shown that this study had negligible heterogeneity. Besides, we applied the Begg's and Egger's test to valuate the publication bias and used funnel plot to detect whether the study is symmetrical, the result indicated that no publication bias was found for OS, thus confirming that the analysis of this study is appropriate and the results of this study are credible.
Our meta-analysis demonstrated several valuable findings, the first valuable finding was that high level of sPD-L1 predicts poor prognosis compared to low level of sPD-L1, it suggested that sPD-L1 could serve as a useful biomarker for cancer prognosis and offer new insight into potential therapeutic strategies. The second valuable finding was that an effective and easily measured method was offered to predict outcome of patients with cancer. Many studies [27] [28] [29] suggest that PD-L1 is a suitable predictor biomarker for prognosis; however, the expression of PD-L1 was tested on tumour cells, and the acquisition of tumour tissue in invasive measure is needed, which is a challenge especially in solid tumour, thus for predict prognosis, sPD-L1 was more convenient and less invasive operation compared with PD-L1.
This meta-analysis has also several limitations; first of all, the meta-analysis was limited to articles published in English, which was more susceptible to some biases in some degree. Secondly, the limitation is the optimal cut-off values of sPD-L1 in each study are different, making it difficult to reach a consensus value. Finally, the number of studies in each cancer type is limited; thus, further well-designed and larger size studies are needed to confirm the results in the future. 
Conclusion
To sum up, this is the first meta-analysis showing that high level of sPD-L1 is an important predictor of poor prognosis in patients with cancer, and sPD-L1 maybe served as a valuable biomarker for cancer prognosis.
